AAAAAA

   
Results: 1-17 |
Results: 17
Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease
Authors: Tarkowski, E Liljeroth, AM Nilsson, A Minthon, L Blennow, K
Citation: E. Tarkowski et al., Decreased levels of intrathecal interleukin 1 receptor antagonist in Alzheimer's disease, DEMENT G C, 12(5), 2001, pp. 314-317
Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients
Authors: Clarke, NA Soininen, H Gustafson, L Minthon, L Alhainen, K Francis, PT
Citation: Na. Clarke et al., Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients, INT J GER P, 16(11), 2001, pp. 1104-1106
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease
Authors: Davidsson, P Blennow, K Andreasen, N Eriksson, B Minthon, L Hesse, C
Citation: P. Davidsson et al., Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease, NEUROSCI L, 300(3), 2001, pp. 157-160
Tacrine and rate of progression in Alzheimer's disease - relation to ApoE allele genotype
Authors: Sjogren, M Hesse, C Basun, H Kol, G Thostrup, H Kilander, L Marcusson, J Edman, A Wallin, A Karlsson, I Troell, M Wachtmaister, G Ekdahl, A Olofsson, H Sandstrom, A Andreasen, N Minthon, L Blennow, K
Citation: M. Sjogren et al., Tacrine and rate of progression in Alzheimer's disease - relation to ApoE allele genotype, J NEURAL TR, 108(4), 2001, pp. 451-458
Cerebrospinal fluid tau and beta-amyloid((I-42)) in dementia disorders
Authors: Vanmechelen, E Vanderstichele, H Hulstaert, F Andreasen, N Minthon, L Winblad, B Davidsson, P Blennow, K
Citation: E. Vanmechelen et al., Cerebrospinal fluid tau and beta-amyloid((I-42)) in dementia disorders, MECH AGE D, 122(16), 2001, pp. 2005-2011
Both total and phosphorylated tau are increased in Alzheimer's disease
Authors: Sjogren, M Davidsson, P Tullberg, M Minthon, L Wallin, A Wikkelso, C Granerus, AK Vanderstichele, H Vanmechelen, E Blennow, K
Citation: M. Sjogren et al., Both total and phosphorylated tau are increased in Alzheimer's disease, J NE NE PSY, 70(5), 2001, pp. 624-630
Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice
Authors: Andreasen, N Minthon, L Davidsson, P Vanmechelen, E Vanderstichele, H Winblad, B Blennow, K
Citation: N. Andreasen et al., Evaluation of CSF-tau and CSF-A beta 42 as diagnostic markers for Alzheimer disease in clinical practice, ARCH NEUROL, 58(3), 2001, pp. 373-379
Standardization of measurement of beta-amyloid((1-42)) in cerebrospinal fluid and plasma
Authors: Vanderstichele, H Van Kerschaver, E Hesse, C Davidsson, P Buyse, MA Andreasen, N Minthon, L Wallin, A Blennow, K Vanmechelen, E
Citation: H. Vanderstichele et al., Standardization of measurement of beta-amyloid((1-42)) in cerebrospinal fluid and plasma, AMYLOID, 7(4), 2000, pp. 245-258
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid
Authors: Hesse, C Larsson, H Fredman, P Minthon, L Andreason, N Davidsson, P Blennow, K
Citation: C. Hesse et al., Measurement of apolipoprotein E (apoE) in cerebrospinal fluid, NEUROCHEM R, 25(4), 2000, pp. 511-517
Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases
Authors: Bretillon, L Siden, A Wahlund, LO Lutjohann, D Minthon, L Crisby, M Hillert, J Groth, CG Diczfalusy, U Bjorkhem, I
Citation: L. Bretillon et al., Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases, NEUROSCI L, 293(2), 2000, pp. 87-90
No association between the alpha 2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression
Authors: Blennow, K Ricksten, A Prince, JA Brookes, AJ Emahazion, T Wasslavik, C Bogdanovic, N Andreasen, N Batsman, S Marcusson, J Nagga, K Wallin, A Regland, B Olofsson, H Hesse, C Davidson, P Minthon, L Jansson, A Palmqvist, L Rymo, L
Citation: K. Blennow et al., No association between the alpha 2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression, J NEURAL TR, 107(8-9), 2000, pp. 1065-1079
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging
Authors: Sjogren, M Minthon, L Davidsson, P Granerus, AK Clarberg, A Vanderstichele, H Vanmechelen, E Wallin, A Blennow, K
Citation: M. Sjogren et al., CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging, J NEURAL TR, 107(5), 2000, pp. 563-579
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD
Authors: Sjogren, M Rosengren, L Minthon, L Davidsson, P Blennow, K Wallin, A
Citation: M. Sjogren et al., Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD, NEUROLOGY, 54(10), 2000, pp. 1960-1964
Cerebrospinal fluid tau and A beta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment
Authors: Andreasen, N Minthon, L Vanmechelen, E Vanderstichele, H Davidsson, P Winblad, B Blennow, K
Citation: N. Andreasen et al., Cerebrospinal fluid tau and A beta 42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment, NEUROSCI L, 273(1), 1999, pp. 5-8
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample
Authors: Andreasen, N Minthon, L Clarberg, A Davidsson, P Gottfries, J Vanmechelen, E Vanderstichele, H Winblad, B Blennow, K
Citation: N. Andreasen et al., Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample, NEUROLOGY, 53(7), 1999, pp. 1488-1494
Cerebrospinal fluid beta-amyloid((1-42)) in Alzheimer disease - Differences between early- and late-onset Alzheimer disease and stability during the course of disease
Authors: Andreasen, N Hesse, C Davidsson, P Minthon, L Wallin, A Winblad, B Vanderstichele, H Vanmechelen, E Blennow, K
Citation: N. Andreasen et al., Cerebrospinal fluid beta-amyloid((1-42)) in Alzheimer disease - Differences between early- and late-onset Alzheimer disease and stability during the course of disease, ARCH NEUROL, 56(6), 1999, pp. 673-680
Decreased monoamine metabolites in frontotemporal dementia and Alzheimer'sdisease
Authors: Sjogren, M Minthon, L Passant, U Blennow, K Wallin, A
Citation: M. Sjogren et al., Decreased monoamine metabolites in frontotemporal dementia and Alzheimer'sdisease, NEUROBIOL A, 19(5), 1998, pp. 379-384
Risultati: 1-17 |